Mark Gladwin, the Jack D. Myers Professor and Chair of the Department of Medicine at the University of Pittsburgh, has been recognized by the American Heart Association as a distinguished scientist, the highest honor bestowed upon a science volunteer by the association. This prestigious title is bestowed on an elite group of scientists whose work has importantly advanced the understanding of cardiovascular disease, stroke and brain health.
Gladwin has published more than 450 manuscripts in the fields of vascular and nitrite biology. Among his major scientific discoveries is the finding that nitrite salt is a biological signaling molecule that regulates physiological and pathological hypoxic responses, blood pressure and flow, and cell function. His studies have translated to the clinical and epidemiological description of pulmonary hypertension and pulmonary complications of sickle cell disease.
Gladwin currently serves as principal investigator on a new multi-center clinical trial of Riociguat to treat patients with sickle cell disease and pulmonary hypertension as well as principal investigator on a multi-center trial, called the “Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange Trial.”